TransMedics Group, Inc.
70.74USD
-1.3200 (-1.83%)
Fetching financial statements from SEC filings…
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on TMDX.
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 190 | 174 | 161 | 144 | 157 | 144 | 122 | 109 |
| Cost of Revenue | 77 | 73 | 67 | 59 | 61 | 55 | 50 | 48 |
| Gross Profit | 113 | 101 | 93 | 85 | 97 | 88 | 72 | 61 |
| Operating Income | 24 | 13 | 21 | 23 | 37 | 27 | 9 | 4 |
| Net Income | 15 | 7 | 105 | 24 | 35 | 26 | 7 | 4 |
| EPS (Diluted) | $0.41 | $0.20 | $2.59 | $0.66 | $0.92 | $0.70 | $0.20 | $0.12 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)